Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Highlights of Merck’s Q4 2023 financial results
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite a modest increase in revenues.
Fourth-quarter worldwide sales increased 6% year-over-year to $14.6 billion, mainly reflecting the sustained growth across oncology and vaccines.
The company reported a net loss of $1.23 billion or $0.48 per share for the December quarter, compared to a profit of $3.02 billion or $1.18 per share in the prior-year period. On an adjusted basis, it was earnings of $0.03 per share in Q4, down 98% from the fourth quarter of 2022.
“As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team,” said Merck’s CEO Robert Davis.
Prior Performance
Most Popular
Key highlights from Nio’s (NIO) Q3 2024 earnings results
NIO Inc. (NYSE: NIO) reported its third quarter 2024 earnings results today. Total revenues were $2.66 billion, down 2.1% from the same period a year ago. Net loss attributable
Key takeaways from Walmart’s (WMT) Q3 2025 report
Over the years, Walmart Inc. (NYSE: WMT) has followed a successful business model focused on offering customers a unique shopping experience and the best prices. While the retail giant continues
What to look for when Macy’s (M) reports its Q3 2024 earnings results
Shares of Macy’s, Inc. (NYSE: M) remained red on Tuesday. The stock has dropped 14% over the past three months. The retailer is scheduled to report its third quarter 2024